<DOC>
	<DOCNO>NCT00484536</DOCNO>
	<brief_summary>The objective study evaluate effect , safety tolerability CDP323 patient relapse form multiple sclerosis</brief_summary>
	<brief_title>Placebo Controlled Study Subjects With Relapsing Forms MS Evaluate Safety , Tolerability Effects CDP323</brief_title>
	<detailed_description />
	<mesh_term>Sclerosis</mesh_term>
	<mesh_term>Multiple Sclerosis</mesh_term>
	<criteria>relapse form MS screen EDSS score 0 5.5 , inclusive least one clinical relapse 12 month screen active disease , define set MRI activity criterion fail prior treatment betainterferons glatiramer acetate sign silent infection , include positive test HIV1 , HIV2 Hepatitis B Hepatitis C tuberculosis know allergy gadoliniumDTPA , and/or ingredient study drug formulation pretreatment immunosuppressive immunomodulatory drug prior screen within certain time frame</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>CDP323</keyword>
	<keyword>Relapsing Multiple Sclerosis</keyword>
	<keyword>Magnetic Resonance Imaging</keyword>
	<keyword>Oral Compound</keyword>
	<keyword>MS</keyword>
</DOC>